Evidence map›Paper›PMID 28814805›Full record

Trial reportScientific reports2017

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.

Hong Jian, Wei Li, Zhiyong Ma, Jianjin Huang, Jifeng Feng, Yong Song, Beili Gao, Huili Zhu, Min Tao, Chong Bai and 6 more

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 1 country.

Hong JianShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Wei LiCancer Center, the First Hospital of Jilin University, Changchun, China.
Zhiyong MaDepartment of Internal Medicine, Henan Cancer Hospital, Zhengzhou, China.
Jianjin HuangDepartment of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Jifeng FengDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Yong SongDepartment of Respiratory Medicine, Nanjing General Hospital of Nanjing Military Command, Nanjing, China.
Beili GaoDepartment of Respiratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huili ZhuDepartment of Respiratory Medicine, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Min TaoDepartment of Oncology, The First Affiliated Hospital of Soochow University, Soochow, China.
Chong BaiDepartment of Respiratory Medicine, Changhai Hospital Affiliated to Shanghai Second Military Medical University, Shanghai, China.
Shenglin MaDepartment of Radiotherapy, Hangzhou First People's Hospital, Hangzhou, China.
Hongming PanDepartment of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Shukui QinDepartment of Medical Oncology, PLA 81 Hospital, Nanjing, China.
Dong HuaDepartment of Medical Oncology, Wuxi Fourth People's Hospital, Wuxi, China.
Yongfeng YuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Shun LuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. shun_lu11@163.com.
Shanghai Jiao Tong University · CN81th Hospital of PLA · CNHangzhou First People's Hospital · CNHenan Cancer Hospital · CNHuadong Hospital · CNJiangsu Cancer Hospital · CNJilin University · CNNanjing General Hospital of Nanjing Military Command · CNRuijin Hospital · CNSecond Affiliated Hospital of Zhejiang University · CNSecond Military Medical University · CNShanghai Chest Hospital · CNSir Run Run Shaw Hospital · CNSoochow University · CNWuxi Fourth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. However, EGFR mutation testing is not attainable in approximately 20% of patients. The current study examined intercalating and maintaining gefitinib treatment in stage IIIB/IV non-squamous NSCLC, never or former light smoking patients with unknown EGFR mutation status. Briefly, 219 patients who achieved stable disease (SD) with gemcitabine (1250 mg/m

Indexed as

AdolescentAdultAgedAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDeoxycytidineDisease-Free SurvivalErbB ReceptorsFemaleGefitinibGemcitabineHumansLung NeoplasmsMaleAntimetabolites, AntineoplasticCarboplatinDeoxycytidineEGFR protein, humanErbB ReceptorsGefitinibGemcitabineProtein Kinase Inhibitors

Identifiers

PMID28814805
PMCPMC5559626
OpenAlexW2744819108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.